Glucocorticoid-Induced Bone Loss: Dietary Supplementation Recommendations to Reduce the Risk for Osteoporosis and Osteoporotic Fractures

Kristen L. Chen, MD; Nicholas P. Gannon, MD; Josef N. Tofte, MD; Bridget E. Shields, MD

Glucocorticoids (GCs) are among the most widely prescribed medications in dermatologic practice. Although GCs are highly effective anti-inflammatory agents, long-term systemic therapy can result in dangerous adverse effects, including GC-induced osteoporosis (GIO), a bone disease associated with a heightened risk for fragility fractures. In the United States, an estimated 10.2 million adults have osteoporosis—defined as a T-score lower than −2.5 measured via a bone densitometry scan—and 43.4 million adults have low bone mineral density (BMD). The prevalence of osteoporosis is increasing, and the diagnosis is more common in females and adults 55 years and older. More than 2 million individuals have osteoporosis-related fractures annually, and the mortality risk is increased at 5 and 10 years following low-energy osteoporosis-related fractures.

Glucocorticoid therapy is the leading iatrogenic cause of secondary osteoporosis. As many as 30% of all patients treated with systemic GCs for more than 6 months develop GIO. Glucocorticoid-induced BMD loss occurs at a rate of 6% to 12% of total BMD during the first year, slowing to approximately 3% per year during subsequent therapy. The risk for insufficiency fractures increases by as much as 75% from baseline in adults with rheumatic, pulmonary, and skin disorders within the first 3 months of therapy and peaks at approximately 12 months.

PRACTICE POINTS
- Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss, and others are only started on therapy once they have sustained an insufficiency fracture.
- Oral GCs should be used at the lowest effective daily dose for the shortest duration possible.
- Patients using topical and intralesional corticosteroids are unlikely to develop GC-induced osteoporosis.
- Patients treated with any GC dose longer than 3 months should undergo calcium and vitamin D supplementation.

Glucocorticoids (GCs) are among the most widely prescribed medications in dermatologic practice. Although considered generally safe and efficacious, prolonged use and high dosing regimens may precipitate GC-induced osteoporosis, which contributes to an increased risk for fragility fractures. Dermatologists using and prescribing GCs must be aware of the risk for GC-induced osteoporosis. This review details the risks for osteoporosis and osteoporotic (OP) fractures in the setting of topical, intralesional, intramuscular, and systemic GC treatment, as well as nutritional supplementation recommendations that may reduce the risk of these adverse effects.
Despite the risks, many long-term GC users never receive therapy to prevent bone loss; others are only started on therapy once they have sustained an insufficiency fracture. A 5-year international observational study including more than 40,000 postmenopausal women found that only 51% of patients who were on continuous GC therapy were undergoing BMD testing and appropriate medical management. This review highlights the existing evidence on the risks of osteoporosis and osteoporotic (OP) fractures in the setting of topical, intraleisional, intramuscular, and systemic GC treatment, as well as recommendations for nutritional supplementation to reduce these risks.

Pathophysiology

The pathophysiology of GIO is multifactorial and occurs in both early and late phases. The early phase is characterized by rapid BMD reduction due to impaired bone resorption. The late phase is characterized by slower and more progressive BMD reduction due to impaired bone formation. At the osteocyte level, GCs decrease cell viability and induce apoptosis. At the osteoblast level, GCs impair cell replication and differentiation and have proapoptotic effects, resulting in decreased cell numbers and subsequent bone formation. At the osteoclast level, GCs increase expression of pro-osteoclastic cytokines and decrease mature osteoclast apoptosis, resulting in an expanded osteoclastic life span and prolonged bone resorption. Indirectly, GCs alter calcium metabolism by decreasing gastrointestinal calcium absorption and impairing renal absorption.

GCs and Osteoporosis

Oral GCs—Glucocorticoid-induced osteoporosis and fracture risk are dose and duration dependent. A study of 244,235 patients taking GCs and 244,235 controls found the relative risk of vertebral fracture was 1.55 (range, 1.20–2.01) for daily prednisone use at less than 2.5 mg, 2.59 (range, 2.16–3.10) for daily prednisone use from 2.5 to 7.4 mg, and 5.18 (range, 4.25–6.31) for daily doses of 7.5 mg or higher; the relative risk for hip fractures was 0.99 (range, 0.82–1.20), 1.77 (range, 1.55–2.02), and 2.27 (range, 1.94–2.66), respectively. Another large retrospective cohort study found that continuous treatment with prednisone 10 mg/d for more than 90 days compared to no GC exposure increased the risk for hip fractures 7-fold and 17-fold for vertebral fractures. Although the minimum cumulative dose of GCs known to cause osteoporosis is not clearly established, the American College of Rheumatology has proposed an algorithm as a basic approach to anticipate, prevent, and treat GIO (Figure). Fracture risk should be assessed in all patients who are prescribed prednisone 2.5 mg/d for 3 months or longer or an anticipated cumulative dose of more than 1 g per year. Patients 40 years and older with anticipated GC use of 3 months or longer should have both a bone densitometry scan and a Fracture Risk Assessment (FRAX) score. The FRAX tool estimates the 10-year probability of fracture in patients aged 40 to 80 years, and those patients can be further risk stratified as low (FRAX <10%), moderate (FRAX 10%–19%), or high (FRAX ≥20%) risk. In patients with moderate to high risk of fracture (FRAX >10%), initiation of pharmacologic treatment or referral to a metabolic bone specialist should be considered. First-line therapy is an oral bisphosphonate, and second-line therapies include intravenous bisphosphonates, teriparatide, denosumab, or raloxifene for patients at high risk for GIO. Adults younger than 40 years with a history of OP fracture or considerable risk factors for OP fractures should have a bone densitometry scan, and, if results are abnormal, the patient should be referred to a metabolic bone specialist. Those with low fracture risk based on bone densitometry and FRAX and those with no risk factors should be assessed annually for bone health (additional risk factors, GC dose and duration, bone densitometry/FRAX if indicated). In addition to GC dose and duration, additional risk factors for GIO, which are factored into the FRAX tool, include advanced age, low body mass index, history of bone fracture, smoking, excessive alcohol use (≥3 drinks/d), history of falls, low BMD, family history of bone fracture, and hypovitaminosis D.

Topical GCs—Although there is strong evidence and clear guidelines regarding oral GIO, there is a dearth of data surrounding OP risk due to treatment with topical GCs. A recent retrospective nationwide Danish study evaluating the risk of osteoporosis and major OP fracture in 723,251 adults treated with potent or very potent topical steroids sought to evaluate these risks. Patients were included if they had filled prescriptions of at least 500 g of topical mometasone or an equivalent alternative. The investigators reported a 3% increase in relative risk of osteoporosis and major OP fracture with doubling of the cumulative topical GC dose (hazard ratio [HR], 1.03 [95% CI, 1.02–1.04] for both). The overall population-attributable risk was 4.3% (95% CI, 2.7%–5.8%) for osteoporosis and 2.7% (95% CI, 1.7%–3.8%) for major OP fracture. Notably, at least 10,000 g of mometasone was required for 1 additional patient to have a major OP fracture. In a commentary based on this study, Jackson noted that the number of patient-years of topical GC use needed for 1 fracture was 4-fold higher than that for high-dose oral GCs (40 mg/d prednisolone for ≥30 days). Another study assessed the effects of topical GCs on BMD in adults with moderate to severe atopic dermatitis over a 2-year period. A significant difference in BMD assessed via bone densitometry of either the lumbar spine or total hip at baseline or at 2-year follow-up was reported for either group treated with corticosteroids (<75 g per month or ≥75 g per month). Of note, the authors did not account for steroid potency, which ranged from class 1 through class 4. Although limited data exist, these studies suggest topical GCs used at conventional doses with appropriate breaks in therapy will not substantially increase risk for GIO or OP fracture; however,
Calcium and vitamin D and lifestyle modifications

Low risk

No further treatment

Monitor with annual clinical fracture risk assessment with BMD testing every 2–3 y depending on risk factors

Women not of childbearing potential and men

Treat with an oral bisphosphonate

Second-line therapy: teriparatide

Other suggested therapies (in order of preference) for high-risk women for whom the above treatments are not appropriate: IV bisphosphonates, denosumab

Women of childbearing potential (not planning a pregnancy during period of OP treatment)

Treat with an oral bisphosphonate

Second-line therapy: teriparatide

Other suggested therapies (in order of preference): IV bisphosphonates, denosumab, raloxifene for PMP women if no other therapy is available

Moderate/High risk

Age <40 y

1. History of OP fracture(s) OR
2. Z score < −3 at hip or spine and prednisone ≥7.5 mg/d OR
3. >10% loss of BMD per year at hip or spine and prednisone ≥7.5 mg/d OR
4. Very high–dose GCs and ≥30 y of age

Age ≥40 y

1. History of OP fracture(s) OR
2. Men ≥50 y and PMP women with a BMD T-score ≤ −2.5 at the hip or spine OR
3. FRAX (GC adjusted) 10-y risk for major OP fracture ≥10% OR
4. FRAX (GC adjusted) 10-y risk for hip fracture >1% OR
5. Very high–dose GCs

Copyright Cutis 2022. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

Therapeutic algorithm for adults treated with glucocorticoids (GCs). BMD indicates bone mineral density; FRAX, Fracture Risk Assessment score; IV, intravenous; OP, osteoporotic; PMP, postmenopausal. Reproduced with permission from Buckley et al.19
in the small subset of patients requiring chronic use
of superpotent topical corticosteroids with other OP risk
factors, transitioning to non–GC-based therapy or ini-
tiating bone health therapy may be advised to improve
patient outcomes. Risk assessment, as in cases of chronic
topical GC use, may be beneficial.

**Intraleisional GCs**—Intraleisional GCs are indicated
for numerous inflammatory conditions including alo-
ppecia areata, discoid lupus erythematosus, keloids, and
granuloma annulare. It generally is accepted that doses
of triamcinolone acetonide should not exceed 20 mg per
session spaced at least 3 weeks apart or up to 40 mg per
month. One study demonstrated that doses of triam-
cinolone diacetate of 25 mg or less were unlikely to pro-
duce systemic effects and were determined to be a safe
dose for intraleisonal injections. A retrospective cross-
sectional case series including 18 patients with alopecia
areata reported decreased BMD in 9 patients receiving
intraleisonal triamcinolone acetonide 10 mg/mL at 4- to
8-week intervals for at least 20 months, with cumulative
doses greater than 500 mg. This was particularly notable
in postmenopausal women and men older than 50 years;
participants with a body mass index less than 18.5 kg/m²,
history of a stress fracture, family history of osteopenia
or osteoporosis, and history of smoking; and those who
did not regularly engage in weight-bearing exercises. Patients receiving long-term (ie, >1 year) intraleional
steroids should be evaluated for osteoporosis risk and
preventative strategies should be considered (ie, regular
weight-bearing exercises, calcium and vitamin D supple-
mentation, bisphosphate therapy). As with topical GCs,
there are no clear guidelines for risk assessment or treat-
ment recommendations for GIO.

**Intramuscular GCs**—The data regarding intramuscular
(IM) GCs and dermatologic disease is severely limited,
and to the best of our knowledge, no studies specifi-
cally assess the risk for GIO or fracture secondary to
intramuscular GCs; however, a retrospective study of
27 patients (4 female, 23 male; mean age, 33 years [range,
12–61 years]) with refractory alopecia areata receiving
IM triamcinolone acetonide (40 mg every 4 weeks for
3–6 months) reported 1 patient (a 56-year-old woman)
with notably decreased bone densitometry from baseline
requiring treatment discontinuation. No other patients
at risk for osteoporosis had decreased BMD from treat-
ment with IM triamcinolone; however, it was noted that
1 month following treatment, 10 of 11 assessed patients
demonstrated decreased levels of morning serum corti-
sol and plasma adrenocorticotropic hormone—despite
baseline levels within reference range—that resolved
3 months after treatment completion, which suggests a
prolonged release of IM triamcinolone and sustained sys-
temic effect. One systematic review of 342 patients with
dermatologic diseases treated with IM corticosteroids
found the primary side effects included dysmenorrhea,
injection-site lipoatrophy, and adrenocortical suppres-
sion, with only a single reported case of low BMD.

Given the paucity of evidence, additional studies are
required to assess the effect of IM triamcinolone on
BMD and risk for major OP fractures with regard to dos-
ing and frequency. As there are no clear guidelines for
osteoporosis evaluation in the setting of intramuscular GCs,
it may be prudent to follow the algorithmic model
recommended for oral steroids when anticipating at least
3 months of intramuscular GCs.

**Diet and Prevention of Bone Loss**

Given the profound impact that systemic GCs have on
osteoporosis and fracture risk and the sparse data regard-
gring risk from topical, intraleional, or intramuscular GCs,
diet and nutrition represent a simple, safe, and potentially
preventative method of slowing BMD loss and mini-
mizing fracture risk. In higher-risk patients, nutritional
assessment in combination with medical therapy also is
likely warranted.

**Calcium and Vitamin D**—Patients treated with any
GC dose longer than 3 months should undergo calcium
and vitamin D optimization. Exceptions for supple-
mentation include certain patients with sarcoidosis,
which can be associated with high vitamin D levels;
patients with a history of hypercalcemia or hypercal-
curia; and patients with chronic kidney disease. In a
meta-analysis including 30,970 patients in 8 randomized
controlled trials, calcium (500–1200 mg/d) and vitamin D
(400–800 IU/d) supplementation reduced the risk of total
fractures by 15% (summary relative risk estimate, 0.85
[95% CI, 0.73–0.98]) and hip fractures by 30% (sum-
mary relative risk estimate, 0.70 [95% CI, 0.56–0.87]).
One double-blind, placebo-controlled clinical trial con-
ducted by the Women’s Health Initiative that included
36,282 postmenopausal women who were taking 1000 mg
of calcium and 400 IU of vitamin D₃ daily for more than
5 years reported an HR of 0.62 (95% CI, 0.38–1.00) for hip
fracture for supplementation vs placebo. Lastly, a 2016
Cochrane Review including 12 randomized trials and
1343 participants reported a 43% lower risk of new ver-
tebreal fractures following supplementation with calcium,
vitamin D₃, or both compared with controls.
Specific recommendations for calcium and vitamin D₃
supplementation vary based on age and sex. The US
Preventive Services Task Force concluded that insuffi-
cient evidence exists to support calcium and vitamin D₃
supplementation in asymptomatic men and premen-
opausal women. The National Osteoporosis Foundation
(NOIF) supports the use of calcium supplementation for
fracture risk reduction in middle-aged and older adults.
Furthermore, the NOF supports the Institute of Medicine
recommendations that men aged 50 to 70 years con-
sume 1000 mg/d of calcium and that women 51 years
and older as well as men 71 years and older consume
1200 mg/d of calcium. The NOF recommends 800 to
1000 IU/d of vitamin D in adults 50 years and older, while
the Institute of Medicine recommends 600 IU/d in adults
70 years and younger and 800 IU/d in adults 71 years and
FOOD FOR THOUGHT

Food for thought: More studies are needed to determine if probiotics alone may be beneficial in promoting bone health by improving calcium homeostasis, reducing risk for hyperparathyroidism secondary to GC therapy, and decreasing age-related bone resorption. An animal study demonstrated that probiotics can regulate bone resorption and formation as well as reduce bone loss secondary to GC therapy. A randomized, double-blind, placebo-controlled, multicenter trial randomly assigned 249 healthy, early postmenopausal women to receive probiotic treatment containing 3 lactobacillus strains (Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, and L plantarum DSM 15313) or placebo once daily for 12 months. Bone mineral density was measured at baseline and at 12 months. Of the 234 participants who completed the study, lactobacillus treatment reduced lumbosacral BMD loss compared to the placebo group (mean difference, 0.71% [95% CI, 0.06-1.35]). They also reported significant lumbosacral BMD loss in the placebo group (−0.72% [95% CI, −1.22 to −0.22]) compared to no BMD loss in the group treated with lactobacillus (−0.01% [95% CI, −0.50 to 0.48]). Although the data may be encouraging, more studies are needed to determine if probiotics should be regarded as an adjuvant treatment to calcium, vitamin D, and pharmacologic therapy for long-term prevention of bone loss in the setting of GIO. Because existing studies on probiotics include varying compositions and doses, larger studies with consistent supplementation are required. Encouraging probiotic intake through fermented dairy products may represent a simple low-risk intervention to support bone health.

Anti-inflammatory diet—The traditional Mediterranean diet is rich in fruits, vegetables, fish, nuts, whole grains, legumes, and monounsaturated fats and low in meat and dairy products. The Mediterranean diet has been shown to be modestly protective against osteoporosis and fracture risk. A large US observational study including 93,676 women showed that those with the highest quintile of the alternate Mediterranean diet score had a lower risk for hip fracture (HR, 0.80 [95% CI, 0.66-0.97]), with an absolute risk reduction of 0.29% and number needed to treat at 342. A multicenter study involving adults from 8 European countries found that increased adherence to the Mediterranean diet was associated with a 7% reduction in hip fracture incidence (HR per 1 unit increase in Mediterranean diet, 0.93 [95% CI, 0.89-0.98]). High vegetable and fruit intake was associated with decreased hip fracture incidence (HR, 0.86 and 0.89 [95% CI, 0.79-0.94 and 0.82-0.97, respectively]), and high meat and excessive ethanol consumption were associated with increased fracture incidence (HR, 1.18 and 1.74 [95% CI, 1.06-1.31 and 1.32-2.31, respectively]). Similarly, a large observational study in Sweden that included 37,903 men and 33,403 women reported similar findings, noting a 6% lower hip fracture rate per one unit increase in alternate Mediterranean diet score (adjusted HR, 0.94 [95% CI, 0.92-0.96]). This is thought to be due in part to higher levels of dietary vitamin D present in many foods traditionally included in the Mediterranean diet. Additionally, olive oil, a staple in the Mediterranean diet, appears to reduce bone loss by promoting osteoblast proliferation and maturation, inhibiting bone resorption, suppressing oxidative stress and inflammation, and increasing calcium deposition in the extracellular matrix. Fruits, vegetables, legumes, and nuts also are rich in minerals including potassium and magnesium, which are important in bone health to promote osteoblast proliferation and vitamin D activation.

Final Thoughts
Osteoporosis-related fractures are common and are associated with high morbidity and health care costs. Dermatologists using and prescribing corticosteroids must be aware of the risk for GIO, particularly in patients with a pre-existing diagnosis of osteopenia or osteoporosis. There likely is no oral corticosteroid dose that does not increase a patient’s risk for osteoporosis; therefore, oral GCs should be used at the lowest effective daily dose for the shortest duration possible. Patients with an anticipated duration of at least 3 months—regardless of dose—should be assessed for their risk for GIO. Patients using topical and intraloskeletal corticosteroids are unlikely to develop GIO; however, those with risk factors and a considerable cumulative dose may warrant further evaluation. In all cases, we advocate for supplementing with calcium and vitamin D as well as promoting probiotic intake and the Mediterranean diet. Those at moderate to high risk for fracture may require additional medical therapy. Dermatologists are uniquely positioned to identify this at-risk population, and because osteoporosis is a chronic illness, primary care providers should be notified of prolonged GC therapy to help with risk assessment, initiation of vitamin and mineral supplementation, and follow-up with metabolic bone health specialists. Through a multidisciplinary approach and patient education, GIO and the potential risk for fracture can be successfully mitigated in most patients.

REFERENCES
FOOD FOR THOUGHT

11. 7.
13. 6.
15. 4.
17. 2.
19. 1.
21. 1

14. 12.
16. 10.
18. 8.
20. 6.
22. 4.
24. 2.